This system also confers additional stability on the baculovirus genome, and gives rise to AAV vectors that achieve higher levels of infectivity — potentially enabling greater therapeutic ...

Presentations will feature insights into optimizing VP1 ratios and the development of a high-yielding scalable Sf9-baculovirus platform for AAV production. Lexeo is developing therapies targeting ...

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company ...

"We are particularly proud of our exciting preclinical data in amyotrophic lateral sclerosis (ALS), Huntington’s disease, and ...

“The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality,” said José Manuel Otero, Chief Technical ...